Content in this section contains off-label information and information on medicines that are not Medsafe registered. No recommendations regarding safety and efficacy can be made for unregistered medicines. Treatment decisions based on unregistered medicines are the full responsibility of the prescribing physician.Where Roche products are referred to in presentations, please review the full Data Sheet at www.medsafe.govt.nz before prescribing.

 

Roche and Genentech at

ESMO 2020

September 19 - September 21        Madrid, Spain       esmo.org

 

IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

Harbeck N, et al.

 

Description

IMpassion031 is a global, phase III, multicentre, double-blind, randomised, placebo-controlled study in patients with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadjuvant atezolizumab or placebo with nab-paclitaxel followed by atezolizumab or placebo with dose-dense doxorubicin + cyclophosphamide. Here, we report the primary analysis of IMpassion031.

Patient (pt) preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

O’Shaughnessy J, et al.

 

Description

PHranceSCa is a phase II study evaluating patient preference for the fixed-dose combination of PERJETA and Herceptin for subcutaneous injection versus PERJETA and Herceptin intravenous infusions in patients with HER2-positive early breast cancer. The current mini-oral will present patient preference and satisfaction data, along with healthcare professional perception and safety data (including when switching formulations), from the primary analysis.

 

 

IMpassion130: Final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in patients with previously untreated locally advanced or metastatic triple-negative breast cancer

Emens LA, et al.

 

Description

IMpassion130 is a Phase III study evaluating atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in PD-L1+ metastatic triple-negative breast cancer. Here we report prespecified final OS and long-term safety results.

Ipatasertib + paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: Primary results from Cohort B of the IPATunity130 randomised trial

Turner N, et al.

 

Description

Cohort B of the randomised phase III IPATunity130 trial evaluated the effect of combining the oral AKT inhibitor ipatasertib with paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer requiring chemotherapy. Results of the primary analysis of Cohort B are reported in a mini oral presentation at ESMO.

 

 

Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of 1st-line paclitaxel ± atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Miles D, et al.

 

Description

IMpassion131 is a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel ± atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Here we report primary analysis of IMpassion131.

Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy ∓ atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Moore K, et al.

 

Description

IMagyn050 is a phase 3 study investigating the efficacy and safety of atezolizumab▼ versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab▼ to patients with newly-diagnosed stage III or stage IV ovarian cancer. In the current presentation, the co-primary endpoints of the study (PFS and OS in the ITT and PD-L1+ populations) are presented.

  • Educational material breast cancer
Close